Completed PHASE3 INTERVENTIONAL 1-arm NCT01256671

DHEA Against Vaginal Atrophy - Safety Study of 12 Months

Sponsor: EndoCeutics Inc.

Interventions DHEA

Updated 9 times since 2017 Last updated: Sep 15, 2017 Started: Dec 31, 2010 Primary completion: Jul 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Vaginal Atrophy, this trial is completed. The trial is conducted by EndoCeutics Inc. and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Nov 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Nov 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EndoCeutics Inc.

Data source: EndoCeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bathurst, Canada , Beachwood, United States , Boynton Beach, United States , Calgary, Canada , Charlottesville, United States , Cleveland, United States , Columbus, United States , Denver, United States , Drummondville, Canada and 27 more locations